First: immune turbidimetry technology.
Second: solid-phase enzyme immunoassay technology.
Third: immunofluorescence technology.
Fourthly, flow cytometry.
Fifthly, colloidal gold technology.
Molecular diagnosis is a technique to detect the changes of genetic material structure or expression level in patients by molecular biological methods, and then make a diagnosis. It provides more accurate information for the prevention, prediction, diagnosis, treatment and prognosis of diseases.
Looking at the global molecular diagnostic market structure, Roche is the largest molecular diagnostic company, followed by Novartis, Gen-Probe, Qiagen, BD, Cepheid, Abbott and Siemens. According to the "TOP 14 Ranking of Global Molecular Diagnostics Companies in 20 13" recently published by GEN website, Roche Diagnostics' revenue in 20 12 was $175.6 billion, ranking first, while other listed companies' revenue in the field of molecular diagnosis was mostly in the billions of dollars.
Thanks to the first patent of PCR (polymerase chain reaction) technology, Roche has obvious advantages in high efficiency and highly integrated automation through the integration of instruments and reagents, so it has a leading position in the field of blood screening.